ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?

Ann Surg Oncol. 2024 Dec 27. doi: 10.1245/s10434-024-16821-5. Online ahead of print.

Thomas E Pennington^{1

2

3}, John F Thompson^{4

5

6}, Alex H R Varey^{4

6

7}

¹ Melanoma Institute Australia, Wollstonecraft, NSW, Australia. [email protected].
² Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. [email protected].
³ Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. [email protected].
⁴ Melanoma Institute Australia, Wollstonecraft, NSW, Australia.
⁵ Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
⁶ Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
⁷ Department of Plastic and Reconstructive Surgery, Westmead Hospital, Westmead, NSW, Australia.

No abstract available